The authors thank current and previous members of their laboratories, particularly Alexander Sumaroka, Malgorzata Swider, Alejandro J. Roman, Jason Charng, Alexandra V. Garafalo, Arun K. Krishnan, Brianna Lisi, Evelyn P. Semenov, Rebecca Sheplock, Christian A. Powers, Valeryia Aksianiuk, and Robert Russell for their participation in the research. The authors also thank all their collaborators, particularly Geoffrey K. Aguirre, Gustavo D. Aguirre, William A. Beltran, Shannon E. Boye, Sanford L. Boye, Alexander M. Dizhoor, Gerald A. Fishman, William W. Hauswirth, Elise Heon, Edwin M. Stone, and Anand Swaroop for their contributions in helping better understand human CEP290 and GUCY2D retinopathies.
Supported by grants from ProQR Therapeutics, Sanofi Genzyme, National Institutes of Health, Macula Vision Research Foundation, The Chatlos Foundation, Hope for Vision, Foundation Fighting Blindness, and Research to Prevent Blindness.
Disclosure: A.V. Cideciyan, ProQR (F), Sanofi Genzyme (F); S.G. Jacobson, ProQR (F), Sanofi Genzyme (F)